Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “FGFR3”

54 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 54 results

Testing effectiveness (Phase 2)Looking for participantsNCT07169279
What this trial is testing

Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)

Who this might be right for
Achondroplasia
QED Therapeutics, a BridgeBio company 77
Testing effectiveness (Phase 2)Study completedNCT00866138
What this trial is testing

Masitinib in Relapse or Refractory Multiple Myeloma With t(4/14) Translocation Expressing or Not FGFR3

Who this might be right for
Multiple Myeloma
AB Science 24
Testing effectiveness (Phase 2)Study completedNCT01752920
What this trial is testing

Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations

Who this might be right for
Solid Tumor
Basilea Pharmaceutica 119
Testing effectiveness (Phase 2)Study completedNCT03401073
What this trial is testing

IVIg for Small Fiber Neuropathy With Autoantibodies TS-HDS and FGFR3

Who this might be right for
Small Fiber NeuropathyIdiopathic Peripheral Neuropathy
Beth Israel Deaconess Medical Center 20
Testing effectiveness (Phase 2)Looking for participantsNCT04945148
What this trial is testing

Oxidative Phosphorylation Targeting In Malignant Glioma Using Metformin Plus Radiotherapy Temozolomide

Who this might be right for
Glioblastoma, IDH-wildtype
Hopital Foch 640
Not applicableStudy completedNCT00106977
What this trial is testing

Clinical Study of Muenke Syndrome (FGFR3-Related Craniosynostosis)

Who this might be right for
CraniosynostosisMuenke Syndrome
National Human Genome Research Institute (NHGRI) 137
Testing effectiveness (Phase 2)Ended earlyNCT02706691
What this trial is testing

BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer

Who this might be right for
FGFR Gene AmplificationFGFR1 Gene AmplificationFGFR2 Gene Amplification+7 more
University of Chicago 1
Testing effectiveness (Phase 2)Ended earlyNCT00872300
What this trial is testing

PHA-739358 for the Treatment of Multiple Myeloma

Who this might be right for
Multiple Myeloma
Nerviano Medical Sciences 7
Testing effectiveness (Phase 2)Ended earlyNCT05363605
What this trial is testing

[225Ac]-FPI-1966 in Participants With Advanced Solid Tumours

Who this might be right for
Advanced Solid TumorHead and Neck Squamous Cell CarcinomaBladder Carcinoma+11 more
Fusion Pharmaceuticals Inc. 6
Early research (Phase 1)Looking for participantsNCT05614739
What this trial is testing

FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3

Who this might be right for
Urinary Bladder NeoplasmsNeoplasm MetastasisUreteral Neoplasms
Eli Lilly and Company 677
Testing effectiveness (Phase 2)Active Not RecruitingNCT04917809
What this trial is testing

Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer

Who this might be right for
Bladder CancerRecurrent Bladder CancerFGFR3 Gene Mutation
Memorial Sloan Kettering Cancer Center 20
Not applicableEnded earlyNCT05052372
What this trial is testing

Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib

Who this might be right for
Bladder CancerUrothelial CarcinomaTransitional Cell Carcinoma+10 more
xCures 2
Not applicableLooking for participantsNCT07388966
What this trial is testing

Prospective Longitudinal Multicentric Study to Measure Limb Movement in Patients With FGFR3-related Skeletal Dysplasia

Who this might be right for
AchondroplasiaHypochondroplasia
SYSNAV 140
Testing effectiveness (Phase 2)Study completedNCT04265651
What this trial is testing

Study of Infigratinib in Children With Achondroplasia

Who this might be right for
Achondroplasia
QED Therapeutics, a BridgeBio company 84
Testing effectiveness (Phase 2)Study completedNCT04919642
What this trial is testing

Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma

Who this might be right for
CholangiocarcinomaFGFR2 FusionFGFR2 Gene Mutation+2 more
TransThera Sciences (Nanjing), Inc. 55
Testing effectiveness (Phase 2)UnknownNCT02278978
What this trial is testing

BIBF1120 in Patients With Advanced FGFR3 Mutated,Overexpressed,or Wild Type Urothelial Carcinoma

Who this might be right for
Urothelial Carcinoma
National Taiwan University Hospital 129
Large-scale testing (Phase 3)Ended earlyNCT04197986
What this trial is testing

Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations

Who this might be right for
Upper Tract Urothelial CarcinomasUrothelial Bladder Cancer
QED Therapeutics, a BridgeBio company 39
Early research (Phase 1)Ended earlyNCT05242822
What this trial is testing

Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations

Who this might be right for
Solid Tumor, AdultIntrahepatic CholangiocarcinomaUrothelial Carcinoma
Kinnate Biopharma 54
Testing effectiveness (Phase 2)WithdrawnNCT05222165
What this trial is testing

Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations

Who this might be right for
Advanced Solid TumorCNS TumorRecurrent WHO Grade II Glioma
Helsinn Healthcare SA
Not applicableUnknownNCT04921553
What this trial is testing

Real Word European Registry of NTRK Fusions and Other Rare Actionable Fusions (TRacKING)

Who this might be right for
CancerCancer MetastaticNTRK Gene Fusion Overexpression+13 more
Centre Leon Berard 500
Next Page